Formulation and assessment of hydroxyzine HCL solid lipid nanoparticles by dual emulsification technique for transdermal delivery

El-Telbany, Dalia Farag A.; El-Telbany, Rania Farag A.; Zakaria, Sherin; Ahmed, Kawkab A.; El-Feky, Yasmin A.

doi:10.1016/j.biopha.2021.112130

Cited by 15 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimum value for PDI is <0.3, which will be accepted to reflect the homogeneous distribution of the nanoparticles. The PDI should be as low as possible (ideally, nearly zero), hence, the size distribution is unimodal (El-Telbany et al., 2021 ). Nanocarriers PS is a crucial determinant of the drug fate in-vivo , as smaller nanocarriers in size permit greater trans-cellular uptake than larger ones.…”

Section: Resultsmentioning

confidence: 99%

“…At predetermined time intervals, 2-ml samples of the receiver medium were withdrawn and replaced by an equivalent fresh medium volume to maintain both constant volume and sink conditions. The amount of PIP in receiver medium samples was determined by UV spectrophotometry at 425 nm (Abbas et al., 2018 ; El-Telbany et al., 2021 ). Release data from CU, PIP suspensions, and different BLs formulations were fitted to zero, first-order, and Higuchi equations using DD solver software.…”

Section: Methodsmentioning

confidence: 99%

“…The surface morphology of synthesized PIP-loaded BLs, including shape and surface was evaluated by transmission electron microscopy, TEM (JEM-2100; JEOL, Japan). The sample was diluted with double distilled water and then placed on a copper grid that was coated with carbon (El-Telbany et al., 2021 ).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Development and optimization of curcumin analog nano-bilosomes using 2¹.3¹full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay

et al. 2022

Self Cite

View full text Add to dashboard Cite

Curcumin (CU) is a natural polyphenolic phytoingredient. CU has anti-inflammatory, anti-oxidant, and anticancer activities. The poor solubility, bioavailability, and stability of CU diminish its clinical application. Hence, structural modification of CU is highly recommended. The CU analog; 3,5-bis(4-bromobenzylidene)-1-propanoylpiperidin-4-one (PIP) exhibited high stability, safety, and more potent antiproliferative activity against hepatocellular carcinoma. In the present study, nano-bilosomes (BLs) were formulated to augment PIP delivery and enhance its solubility. A 2 1 .3 1 full factorial design was adopted to prepare the synthesized PIP-loaded BLs. Optimized F4 showed a biphasic release pattern extended over 24 h, with EE%, ZP, and PS of 90.21 ± 1.0%, −27.05 ± 1.08 mV, and 111.68 ± 1.4 nm. PIP-loaded BLs were tested for safety against a non-cancerous cell line (Wi-38) and for anticancer activity against the Huh-7 human hepatocellular carcinoma cells and compared to the standard anticancer drug doxorubicin (Dox). The anticancer selectivity index of PIP-loaded BLs recorded 420.55 against Huh-7 liver cancer cells, markedly higher than a CU suspension (18.959) or the Dox (20.82). The antiproliferative activity of nano-encapsulated PIP was roughly equivalent to Dox. PIP-loaded BLs, showed enhanced drug solubility, and enhanced anticancer effect, with lower toxicity and higher selectivity against Huh-7 liver cancer cells, compared to the parent CU.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Development and optimization of curcumin analog nano-bilosomes using 2¹.3¹full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…A significant decrease in the VS of the obtained BLs was observed by increasing SDC concentration ( Figure 3 a–c and Figure 4 a–c). This result can be attributed to the enhanced flexibility of bilosomes [ 43 ].…”

Section: Resultsmentioning

confidence: 99%

A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer’s Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes

et al. 2022

Self Cite

View full text Add to dashboard Cite

Impaired memory and cognitive function are the main features of Alzheimer’s disease (AD). Unfortunately, currently available treatments cannot cure or delay AD progression. Moreover, the blood–brain barrier hampers effective delivery of treatment to the brain. Therefore, we aimed to evaluate the impact of intranasally delivered luteolin on AD using bile-salt-based nano-vesicles (bilosomes). Different bilosomes were prepared using 23-factorial design. The variables were defined by the concentration of surfactant, the molar ratio of cholesterol:phospholipid, and the concentration of bile salt. Results demonstrated optimized luteolin-loaded bilosomes with particle size (153.2 ± 0.98 nm), zeta potential (−42.8 ± 0.24 mV), entrapment efficiency% (70.4 ± 0.77%), and % drug released after 8 h (80.0 ± 1.10%). In vivo experiments were conducted on an AD mouse model via intracerebroventricular injection of 3 mg/kg streptozotocin. We conducted behavioral, biochemical marker, histological, and immune histochemistry assays after administering a luteolin suspension or luteolin bilosomes (50 mg/kg) intranasally for 21 consecutive days. Luteolin bilosomes improved short-term and long-term spatial memory. They also exhibited antioxidant properties and reduced levels of proinflammatory mediators. They also suppressed both amyloid β aggregation and hyperphosphorylated Tau protein levels in the hippocampus. In conclusion, luteolin bilosomes are an effective, safe, and non-invasive approach with superior cognitive function capabilities compared to luteolin suspension.

show abstract

“…The anti-pruritic efficacy of the formulation was demonstrated using a 2,4-Dinitrochlorobenzene-induced AD lesion model in mice, and the results were further supported by histopathological examinations. Furthermore, the study investigated the effect of HHCL transdermal gel loaded with SLNs on the levels of IL-4 and substance P. The findings revealed a decrease in the levels of IL-4 and substance P, indicating the potential of the formulation in modulating the inflammatory response associated with AD [ 95 ].…”

Section: Nanotechnological Approaches: For Effective Treatment Of Ato...mentioning

confidence: 99%

Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis

Kakkar,

Saini,

Singh

2023

Pharmacol. Rep

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by a burning sensation and eczematous lesions in diverse portions of the body. The treatment of AD is exclusively focused to limit the itching, reduce inflammation, and repair the breached barrier of the skin. Several therapeutic agents for the treatment and management of AD have been reported and are in use in clinics. However, the topical treatment of AD has been an unswerving challenge for the medical fraternity owing to the impaired skin barrier function in this chronic skin condition. To surmount the problems of conventional drug delivery systems, numerous nanotechnology-based formulations are emerging as alternative new modalities for AD. Latter enhances the bioavailability and delivery to the target disease site, improves drug permeation and therapeutic efficacy with reduced systemic and off-target side effects, and thus improves patient health and promotes compliance. This review aims to describe the various pathophysiological events involved in the occurrence of AD, current challenges in treatment, evidence of molecular markers of AD and its management, combinatorial treatment options, and the intervention of nanotechnology-based formulations for AD therapeutics. Graphical abstract

show abstract

Formulation and assessment of hydroxyzine HCL solid lipid nanoparticles by dual emulsification technique for transdermal delivery

Cited by 15 publications

References 33 publications

Development and optimization of curcumin analog nano-bilosomes using 2¹.3¹full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay

Development and optimization of curcumin analog nano-bilosomes using 2¹.3¹full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay

A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer’s Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes

Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis

Contact Info

Product

Resources

About

Formulation and assessment of hydroxyzine HCL solid lipid nanoparticles by dual emulsification technique for transdermal delivery

Cited by 15 publications

References 33 publications

Development and optimization of curcumin analog nano-bilosomes using 21.31full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay

Development and optimization of curcumin analog nano-bilosomes using 21.31full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay

A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer’s Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes

Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis

Contact Info

Product

Resources

About

Development and optimization of curcumin analog nano-bilosomes using 2¹.3¹full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay

Development and optimization of curcumin analog nano-bilosomes using 2¹.3¹full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay